BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 25918163)

  • 1. RWD Domain as an E2 (Ubc9)-Interaction Module.
    Alontaga AY; Ambaye ND; Li YJ; Vega R; Chen CH; Bzymek KP; Williams JC; Hu W; Chen Y
    J Biol Chem; 2015 Jul; 290(27):16550-9. PubMed ID: 25918163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation.
    Mascle XH; Lussier-Price M; Cappadocia L; Estephan P; Raiola L; Omichinski JG; Aubry M
    J Biol Chem; 2013 Dec; 288(51):36312-27. PubMed ID: 24174529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into E3 ligase activity revealed by a SUMO-RanGAP1-Ubc9-Nup358 complex.
    Reverter D; Lima CD
    Nature; 2005 Jun; 435(7042):687-92. PubMed ID: 15931224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stable chemical SUMO1-Ubc9 conjugate specifically binds as a thioester mimic to the RanBP2-E3 ligase complex.
    Sommer S; Ritterhoff T; Melchior F; Mootz HD
    Chembiochem; 2015 May; 16(8):1183-9. PubMed ID: 25917782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unique binding interactions among Ubc9, SUMO and RanBP2 reveal a mechanism for SUMO paralog selection.
    Tatham MH; Kim S; Jaffray E; Song J; Chen Y; Hay RT
    Nat Struct Mol Biol; 2005 Jan; 12(1):67-74. PubMed ID: 15608651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEL-18 interacts with HSF2 and the SUMO E2 UBC9 to inhibit HSF2 sumoylation.
    Zhang J; Goodson ML; Hong Y; Sarge KD
    J Biol Chem; 2008 Mar; 283(12):7464-9. PubMed ID: 18211895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noncovalent interaction between Ubc9 and SUMO promotes SUMO chain formation.
    Knipscheer P; van Dijk WJ; Olsen JV; Mann M; Sixma TK
    EMBO J; 2007 Jun; 26(11):2797-807. PubMed ID: 17491593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamin interacts with members of the sumoylation machinery.
    Mishra RK; Jatiani SS; Kumar A; Simhadri VR; Hosur RV; Mittal R
    J Biol Chem; 2004 Jul; 279(30):31445-54. PubMed ID: 15123615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SIM-dependent enhancement of substrate-specific SUMOylation by a ubiquitin ligase in vitro.
    Parker JL; Ulrich HD
    Biochem J; 2014 Feb; 457(3):435-40. PubMed ID: 24224485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structure of UBA2(ufd)-Ubc9: insights into E1-E2 interactions in Sumo pathways.
    Wang J; Taherbhoy AM; Hunt HW; Seyedin SN; Miller DW; Miller DJ; Huang DT; Schulman BA
    PLoS One; 2010 Dec; 5(12):e15805. PubMed ID: 21209884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural insights into the regulation of the human E2∼SUMO conjugate through analysis of its stable mimetic.
    Goffinont S; Coste F; Prieu-Serandon P; Mance L; Gaudon V; Garnier N; Castaing B; Suskiewicz MJ
    J Biol Chem; 2023 Jul; 299(7):104870. PubMed ID: 37247759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observation of an E2 (Ubc9)-homodimer by crystallography.
    Alontaga AY; Ambaye ND; Li YJ; Vega R; Chen CH; Bzymek KP; Williams JC; Hu W; Chen Y
    Data Brief; 2016 Jun; 7():195-200. PubMed ID: 27408909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rhes, a physiologic regulator of sumoylation, enhances cross-sumoylation between the basic sumoylation enzymes E1 and Ubc9.
    Subramaniam S; Mealer RG; Sixt KM; Barrow RK; Usiello A; Snyder SH
    J Biol Chem; 2010 Jul; 285(27):20428-32. PubMed ID: 20424159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of small ubiquitin-like modifier 1 (SUMO1) protein specificity, E3 ligase, and SUMO-RanGAP1 binding activities of nucleoporin RanBP2.
    Gareau JR; Reverter D; Lima CD
    J Biol Chem; 2012 Feb; 287(7):4740-51. PubMed ID: 22194619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure and analysis of a complex between SUMO and Ubc9 illustrates features of a conserved E2-Ubl interaction.
    Capili AD; Lima CD
    J Mol Biol; 2007 Jun; 369(3):608-18. PubMed ID: 17466333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
    Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
    J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA repair and global sumoylation are regulated by distinct Ubc9 noncovalent complexes.
    Prudden J; Perry JJ; Nie M; Vashisht AA; Arvai AS; Hitomi C; Guenther G; Wohlschlegel JA; Tainer JA; Boddy MN
    Mol Cell Biol; 2011 Jun; 31(11):2299-310. PubMed ID: 21444718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of an N-terminal site of Ubc9 in SUMO-1, -2, and -3 binding and conjugation.
    Tatham MH; Kim S; Yu B; Jaffray E; Song J; Zheng J; Rodriguez MS; Hay RT; Chen Y
    Biochemistry; 2003 Aug; 42(33):9959-69. PubMed ID: 12924945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism of E1-E2 interaction for the inhibition of Ubl adenylation.
    Wang J; Cai S; Chen Y
    J Biol Chem; 2010 Oct; 285(43):33457-33462. PubMed ID: 20682785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative allosteric mechanisms can regulate the substrate and E2 in SUMO conjugation.
    Karaca E; Tozluoğlu M; Nussinov R; Haliloğlu T
    J Mol Biol; 2011 Mar; 406(4):620-30. PubMed ID: 21216249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.